Compare AMTX & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMTX | ACRV |
|---|---|---|
| Founded | 2005 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 98.6M | 82.2M |
| IPO Year | 2023 | 2022 |
| Metric | AMTX | ACRV |
|---|---|---|
| Price | $2.50 | $1.69 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $12.00 | $11.67 |
| AVG Volume (30 Days) | ★ 1.7M | 493.5K |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.98 | 15.13 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $77,194,000.00 | N/A |
| Revenue This Year | $49.77 | N/A |
| Revenue Next Year | $57.87 | $568.17 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 174.60 | N/A |
| 52 Week Low | $1.30 | $1.05 |
| 52 Week High | $3.80 | $3.56 |
| Indicator | AMTX | ACRV |
|---|---|---|
| Relative Strength Index (RSI) | 48.84 | 43.24 |
| Support Level | $2.18 | $1.51 |
| Resistance Level | $2.68 | $1.86 |
| Average True Range (ATR) | 0.25 | 0.12 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 39.65 | 18.81 |
Aemetis Inc is an renewable fuel and biochemicals company focused on the production of renewable fuels and chemicals through the acquisition, development and commercialization of technologies that replace traditional petroleum-based products through the conversion of first-generation ethanol and biodiesel plants into biorefineries. It owns and operates an approximately 65 million gallon per year ethanol production facility located in Keyes, California. In addition to low carbon renewable fuel ethanol, the Keyes Plant produces Wet Distillers Grains, Distillers Corn Oil, and Condensed Distillers Solubles, all of which are sold to local dairies and feedlots as animal feed. It operates in the reportable geographic segments of North America and India.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.